HPV vaccination rates vary significantly across Europe, with coverage highest among girls in the Nordic countries, Spain and Portugal, while boys in parts of Central and Eastern Europe remain far less likely to be vaccinated.
Data from the European Centre for Disease Prevention and Control (ECDC) highlight disparities in access to and uptake of the vaccine against human papillomavirus (HPV), a common infection that can cause several types of cancer years after exposure.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
The vaccine offers an effective way to prevent HPV-related cancers, but its impact depends on vaccination coverage, access to healthcare and public confidence.
HPV Vaccination Can Prevent Several Cancers
HPV is a group of viruses, some of which spread through sexual contact. Most infections clear naturally, but certain strains can persist and cause cancer, including cervical cancer and other cancers affecting both women and men. Cervical cancer alone kills around 280,000 women worldwide each year.
HPV vaccines have been authorised in the European Union since 2006. Most European countries recommend vaccination for girls and boys by age 15, with catch-up vaccination available for those who missed it earlier. National recommendations are available through the ECDC vaccination schedule.
Although vaccination has traditionally involved two doses, dozens of countries have adopted a single-dose schedule. Studies suggest that one dose may provide protection against the HPV strains most likely to cause cancer, although recommendations differ between countries.
Vaccination Coverage Varies Across Europe
Portugal has one of Europe’s highest vaccination rates, with 95% of girls receiving all recommended doses by age 15. In Bulgaria, the figure is just 4%.
Coverage among boys is generally lower, partly because many countries introduced gender-neutral vaccination programmes more recently. Rates range from 94% in Portugal to just 1% in Romania, according to a European Commission and OECD report.
Across the countries included in the data, an average of 64% of girls and 51% of boys had completed their recommended vaccination by age 15. Both figures remain below the EU target of vaccinating 90% of girls, according to the ECDC.
The differences reflect more than national vaccination policies. School-based programmes, access to healthcare, public confidence and the ability to reach families all influence uptake.
School Programmes Help Improve Coverage
Several countries are introducing targeted initiatives to close the vaccination gap.
Sweden has expanded catch-up vaccination for women who missed immunisation earlier in life as part of its ambition to become the first country to eliminate cervical cancer. By 2025, 91% of girls and 87% of boys in Sweden had been vaccinated by age 15, among the smallest gender gaps in Europe.
France introduced a school-based HPV vaccination programme in 2023, increasing coverage among 12-year-olds from 31% to 48% in its first year. Bulgaria began offering free HPV vaccination to boys in 2025.
School-based programmes can make vaccination more accessible by reducing the need for families to arrange separate medical appointments, while catch-up campaigns provide another opportunity for those who missed earlier vaccination.
Misinformation Continues To Undermine Uptake
Access is not the only challenge. HPV vaccination rates have declined in some countries, with misinformation on social media identified as one contributing factor in reviews by the nonprofit research group Cochrane.
In Romania, Bulgaria and Croatia, rumours about potential harm and side effects, alongside low trust in health authorities, have contributed to low vaccination uptake, according to a study published in BMJ Public Health.
Cochrane’s analysis of clinical trials and real-world studies involving more than 132 million people found no evidence that HPV vaccination causes commonly reported side effects. It also found that vaccinated teenage girls were 80% less likely to develop cervical cancer than those who were unvaccinated.
Vaccination Before Exposure Is Key
HPV vaccination is most effective when administered before exposure to the virus, which is why health authorities recommend immunising adolescents before they become sexually active.
High vaccination coverage among both girls and boys can protect individuals while helping reduce the circulation of cancer-causing HPV strains across the population.
Europe’s uneven vaccination rates show that scientific evidence alone is not enough. Accessible vaccination programmes, clear communication and trusted health advice will be essential to ensure the vaccine’s cancer-prevention benefits reach more people.